The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1581
ISSUE1581
September 23, 2019
Duaklir Pressair: Another LAMA/LABA Inhaler for COPD
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Duaklir Pressair: Another LAMA/LABA Inhaler for COPD
September 23, 2019 (Issue: 1581)
The FDA has approved Duaklir Pressair (Circassia), a
fixed-dose combination of the long-acting muscarinic
antagonist (LAMA) aclidinium bromide and the longacting
beta2-adrenergic agonist (LABA) formoterol
fumarate, for maintenance treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.